Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Aspirin and Acetaminophen Use and the Risk of Cervical Cancer

Friel, Grace MA1; Liu, Cici S. MD2; Kolomeyevskaya, Nonna V. MD3; Hampras, Shalaka S. PhD4; Kruszka, Bridget BA1; Schmitt, Kristina BS1; Cannioto, Rikki A. EdD1; Lele, Shashikant B. MD3; Odunsi, Kunle O. MD3; Moysich, Kirsten B. PhD1

Journal of Lower Genital Tract Disease: July 2015 - Volume 19 - Issue 3 - p 189–193
doi: 10.1097/LGT.0000000000000104
Original Articles – Cervix and HPV

Objective In this study, we investigated whether regular use of aspirin or acetaminophen was associated with risk of cervical cancer in women treated at an American cancer hospital.

Methods This case-control study included 328 patients with cervical cancer and 1,312 controls matched on age and decade enrolled. Controls were women suspected of having but not ultimately diagnosed with a neoplasm. Analgesic use was defined as regular (at least once per week for ≥6 months), frequent (≥7 tablets/week), very long term (≥11 years), or frequent, long term (≥7 tablets per week for ≥5 years).

Results Compared to nonusers, frequent aspirin use was associated with decreased odds of cervical cancer (odds ratio, 0.53; 95% confidence interval, 0.29-0.97). A slightly larger association was observed with frequent, long-term use of aspirin (odds ratio, 0.46; 95% confidence interval, 0.22-0.95). Acetaminophen use was not associated with the risk of cervical cancer.

Conclusions Our findings suggest that frequent and frequent, long-term use of aspirin is associated with decreased odds of cervical cancer. To our knowledge, this is the first US-based study examining these associations. Given the widespread use of nonsteroidal anti-inflammatory drugs and acetaminophen worldwide, further investigations of the possible role of analgesics in cervical cancer, using a larger sample size with better-defined dosing regimens, are warranted.

Frequent and frequent, long-term use of aspirin may be associated with reduced risk of cervical cancer.

1Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY; 2Department of Obstetrics and Gynecology, University at Buffalo SUNY, Buffalo, NY; 3Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY; and 4Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL

Reprint requests to: Kirsten B. Moysich, MS, PhD, Department of Cancer Pathology and Prevention, Roswell Park Cancer Institute, 346 Carlton House, Elm and Carlton Streets, Buffalo, NY 14263. E-mail:

Drs. Liu and Kolomeyevskaya contributed equally to this work.

None of the authors have any conflicts of interest.

Financial support: Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health under Award Number P50CA159981. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by NCI grant No. 5R01CA126841.

This study was approved by the Roswell Park Cancer Institute institutional review board and included written informed consent from all participants.

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site.

Copyright © 2015 by the American Society for Colposcopy and Cervical Pathology